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Clinicalstudiessuggestthecomorbidityoffunctionalpainsyndromessuchasirritablebowelsyndrome,painfulbladdersyndrome,
chronic pelvic pain, and somatoform disorders approaches 40% to 60%. The incidence of episodic or persistent visceral pain
associated with these “functional” disorders is two to three times higher in women than in men. One of the possible explanations
for this phenomenon is estrogen modulation of viscerovisceral cross-sensitization. While a central site of this modulation has
been shown previously, our studies suggest a peripheral site, the dorsal root ganglion (DRG). Estrogens have remarkably wide
range of functions including modulation of voltage-gated calcium channels (VGCCs) and purinoreceptors (P2Xs). Signiﬁcantly,
inﬂammation dramatically alters purinoception by causing a several fold increase in ATP-activated current, alters the voltage
dependence of P2X receptors, and enhances the expression of P2X receptors increasing neuronal hypersensitivity. Gonadal
hormones are thought as indispensable cornerstones of the normal development and function, but it appears that no body
region, no neuronal circuit, and virtually no cell is unaﬀected by them. Thus, increasing awareness toward estrogens appears
to be obligatory.
1. DRG Neurons and VisceralSensitization
Sex hormones and 17β-estradiol (E2), in particular, directly
inﬂuence the functions of primary aﬀerent neurons. How-
ever, E2 has a multiplicity of actions: membrane, cytoplas-
mic, and nuclear: E2 modulates cellular activity by altering
ion channel opening, G-protein signaling, and activation of
trophic factor-like signal transduction pathways [1]. DRG
neurons in culture express receptors of nociceptive sig-
nals [2] and retain most, if not all, their intracellular sig-
naling cascades. DRG neurons in vitro are a valuable prep-
aration because adult primary sensory neurons can be stud-
ied without the interference of modulation by central or
peripheral messengers. Visceral aﬀerents are sensitive to ATP
[3], and several indirect pieces of evidence suggest that
visceral aﬀerents are E2-sensitive: (i) visceral pain is aﬀected
by hormonal level in cycling females [4]; (ii) there are gen-
der diﬀerences in the prevalence of functional disorders in-
volving the viscera [5]; (iii) putative visceral aﬀerents [6]ﬁ t
into the population of DRG neurons that are E2-sensitive.
Although it is generally accepted that each primary aﬀerent
neuron is a single sensory channel, several studies have chal-
lenged that view and demonstrate that a population of DRG
neuron can innervate both the viscera and somatic tissues.
Both subtypes of estrogen receptors (ERα and ERβ)a r e
present in small-diameter DRG neurons, presumably noci-
ceptors. Relevantly, estrogen receptors are distributed in
regions of the central and peripheral nervous system that
mediate nociception. A large body of the literature supports
the idea that E2 modulates nociceptive responses in pelvic
pain syndromes; however, whether E2 is pro- or antinoci-
ceptive remains unresolved. Within the context of our hy-
pothesis, E2 modulation of nociceptive response depends on
the type of pain, its durations, and the involvement of other
antinociceptive mechanisms. Visceral nociception and noci-
ceptor sensitization appear to be regulated by ATP and sub-
stanceP[7],andDRGisanimportantsiteofvisceralaﬀerent
convergence and cross-sensitization.
Mechanisms of viscerovisceral hyperalgesia between or-
gans with documented partially common sensory projection
probably involve sensitization of visceroviscero-somatic con-
vergent neurons [8]. Within the context of our hypothesis,2 Pain Research and Treatment
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Figure 1: Models of alternative possibilities for viscero-visceral cross-sensitization in the DRG neuron. (a) ATP released by a neuron
innervating the inﬂamed uterus acts on a neighboring neuron sensitizing its responses to colonic distention. (b) The same neuron innervates
the uterus and colon. Uterus inﬂammation directly sensitizes the neuron to colonic distention.
sensory neurons can release an ATP intraganglionically dur-
ing inﬂammation. The inﬂammation in the reproductive
tract can cross-sensitize the response to ATP in colonic
DRGs. Although it has been accepted that each primary af-
ferent neuron is a single sensory channel (Figure 1(a)), sev-
eral studies has challenged that view [9], and our own
data using retrograde labeling demonstrate that popula-
tion of DRG receive sensory input from diﬀerent visceral
organs: uterus and colon [10] and that inﬂammation in the
uterus upregulated nociceptive signaling in the colon [11]
(Figure 1(b)).
2. Transduction of Visceral Nociception
Painisanunpleasantsensoryandemotionalexperienceasso-
ciated with actual or potential damage or depicted in terms
ofsuchdamageandnormaltransmittingpainsystemisabso-
lutely essential to keep the integrity of our body [12]. The
incidence of persistent, episodic, or chronic “functional”
visceral pain associated with functional disorders such as
irritable bowel syndrome, ﬁbromyalgia, painful bladder syn-
drome, chronic pelvic pain, and others is much more prev-
alent in females [13, 14]. A meta-analysis of acute experi-
mentalpainstudies(pressurepainandelectricalstimulation)
using a “box score” methodology in humans shows that fe-
males display greater sensitivity and that pain threshold
and tolerance are modulated across the menstrual cycle [4].
17β-estradiol (E2) may account for these observed ﬂuc-
tuations in pain perception and symptoms [13]. Thus, a
possible explanation is that E2 may have diﬀerent actions on
nociceptive signaling depending on the origin of the noxious
stimulus. The localization of both estrogen receptors ERα
and ERβ in DRG neurons and the attenuation of ATP-in-
duced [Ca2+]i [15] strongly suggest that E2 modulates vis-
ceral pain processing peripherally.
Nociceptors were deﬁned as receptors by Sherrington
more than a century ago (1906) that respond selectively to
stimuli that cause tissue damage. The nociceptors can be
dividedintotwomaingroupsbasedonanatomicalandfunc-
tionalproperties:ActivityinmyelinatedAδ-ﬁbernociceptors
gives rise to the initial sharp feeling of pain while on the
contrary unmyelinated C-ﬁber nociceptors gives rise to the
later, duller, burning pain sensation due to their diﬀerent
morphology. The cell bodies of these axons are located in the
DRG.
The molecular and cellular mechanism of nociception
has been deﬁned during the past two decades. Molecular
function of nociceptors depends on expression of diﬀerent
nociceptive receptors and ion channels that can be activated
by noxious stimuli. These receptors and ion channels detect
speciﬁc physical or chemical stimuli and induce membrane
depolarization. Among these nociceptive receptors and ion
channels, transient receptor potential ion channel (TRP)-re-
latedTRPVfamilyandpurinergicreceptors(P2X2 andP2X3)
have been very well studied and acknowledged as molecular
detectors of noxious thermal, mechanical, or chemical stim-
uli [16]. Visceral nociceptive C-ﬁbers are activated by ATP
released by noxious stimuli from cells in target organs and
have been implicated as mediators of noxious stimulus
intensities [3]. Alteration in signal transduction of primary
aﬀerent neurons can result in enhanced perception of the
visceral sensation, which is common in patients with dif-
ferent disorders resulting in elevated pain perception. Pe-
ripheral sensitization can develop in response to sustain
stimulation, inﬂammation, and nerve injury.
3. Nongenomic Mechanism of Estrogen Action
on Visceral Nociceptors
Both estrogen receptor α (ERα)a n de s t r o g e nr e c e p t o rβ
(ERβ) belong to nuclear receptors of the steroid/thyroid
superfamily,inwhichthemembershavestructuralandfunc-
tional similarities such as a ligand-dependent transcription
factor that modulates gene expression. There is a high ho-
mology between ERα and ERβ in the DNA-binding domainPain Research and Treatment 3
(97%), but a moderate homology in the ligand-binding do-
main (55%), resulting in somewhat lower aﬃnities for en-
dogenous 17α-a n d1 7 β-estradiol to ERβ than ERα.
A variety of cell types respond rapidly to E2, making a
nongenomic mechanism of action. Some nongenomic activ-
ities of estrogens may be explained by the presence of classic
estrogen receptors [17–19], but a brain-speciﬁc ERX has also
been suggested [20]. However, this putative new receptor has
been expressed only in glial cells and can be activated by the
inactive17α-estradiolstereoisomer.Overall,thenongenomic
estrogen eﬀects are thought to be mediated by ERα that is
sequestered to the cytoplasm or the plasma membrane with-
in a signaling complex [1]. The initial evidence for this con-
cept was provided by studies showing that signal transduc-
tion is initiated by estradiol conjugated to large, membrane
impermeant molecules such as bovine serum albumin [15].
The local synthesis of estrogens in the brain provides high
concentrations of estrogens locally. In fact, local synthesis
of estrogens in the brain seems to be a requirement for the
rapid signaling of estrogen receptor since the cyclic changes
ofplasmahormonelevelsaretooslowtoﬁtthisrapidpattern
of activation. Many eﬀects of estradiol in the brain, such as
part of the regulation of lordosis behavior [21] and signaling
in the dorsal root ganglion [7, 18], are in the time range
proposing nonclassic mechanisms.
ERs distributed through CNS and PNS including regions
that mediate nociception. For example, ERs are expressed in
dorsal horn neurons of the spinal cord [22, 23] and DRG
neurons [24]. DRG neurons express both ERα and ERβ in
vivo[25]andinvitro[10].TheseﬁndingssuggestthatE2 may
modulate sensory input at the primary aﬀerent level. E2 can
alter gene transcription, resulting in pronociceptive (reduc-
ing β-endorphin expression) or antinociceptive (increasing
enkephalin expression) changes of endogenous opioid pep-
tides and opioid receptors [22, 26, 27]. E2 can modulate
cellular activity by altering ion channel opening and second
messenger signaling by stimulating G-proteins [15, 28–30],
the signal transduction pathways traditionally associated
with membrane receptor activation. Many of these eﬀects
have been ascribed to membrane-associated receptors [31].
Theresultsfromotherlaboratories[28,32]andourdata[15]
indicate that E2 is acting to modulate L-type VGCC.
Adenosine5-triphosphate(ATP)isoneofthemostcom-
mon chemical compounds in living cells. Neurons represent
a remarkable source of ATP, as a neurotransmitter, which is
widely used in both central and peripheral nervous systems
[33].ATPcanbereleasedfromvesiclepools,oritcanbecore-
leasedand/orcostoredtogetherwithclassicalneurotransmit-
ters in neurons. A decade ago, ATP was shown to be an extra-
cellular signal involved in peripheral hyperalgesia [34]. One
of ATP’s best deﬁned roles has been described in sensory
transduction of noxious stimuli by activating purinergic,
ATP-gated P2X receptors on primary aﬀerent ﬁbers [33].
ATP release from tissues during pathological conditions that
cause tissue damage or inﬂammation activates P2X receptors
on primary aﬀerent ﬁbers innervating the aﬀerent organs
[35].
Some molecular targets have been identiﬁed as key play-
ers in the activation and sensitization of visceral nociceptors,
notably ASICs, TTX-resistant Na channels, and the TRPV1
receptor [36]. TRPV1 receptor is a sensory neuron-speciﬁc
cation channel which belongs to the transient receptor
potential subfamily 1 and plays an important role in trans-
porting thermal and inﬂammatory pain signals. Evidence for
TRPV1’sroleintheirpathogenesiscomesfromstudiesshow-
ingthatmicelackingTRP1Rgenehavedeﬁcitsinthermal-or
inﬂammatory-induced hyperalgesia [37]. Activation of both
TRPV1 and P2X receptors induce mobilization of [Ca2+]i
in cultured DRG neurons [38]. Capsaicin-induced TPRV1
receptor-mediated changes in [Ca2+]i may represent a level
of DRG activation to noxious cutaneous stimulation, while
ATP-induced changes in [Ca2+]i may reﬂect the level of DRG
neuron sensitization to noxious visceral stimuli since ATP
is released by noxious stimuli and tissue damage near the
primary aﬀerent nerve terminals [39].
The expression of transient receptor potential vanilloid
1 (TRPV1) receptors is widespread in several areas of the
n e r v o u ss y s t e m ,b u ti ti sp a r t i c u l a r l ys t r o n gi nD R G .T R P V 1
receptors are at the cellular membrane as well as in the mem-
brane of intracellular calcium stores (e.g., endoplasmatic
reticulum). For pain transmission, the pain/temperature
sensitive TRPV1 receptor is highly expressed in nociceptive
neurons of the peripheral nerve system. TRPV1 receptors
are activated by a wide variety of stimuli, both exogenous
(capsaicin, noxious heat) and endogenous (protons, lipoxy-
genase products, anandamide, dopamine), and they mediate
a nonselective cationic current with particularly high Ca2+
permeability [37]. The potentiating of TRPV1 activity can be
quantiﬁed by measuring the diﬀerences of capsaicin-induced
Ca2+ concentration changes before and after receptor acti-
vation [40]. Signiﬁcantly, a subset of DRG neurons respond
to both capsaicin and ATP [7] indicating that there may
be cross-activation of these receptors that may underlie the
sensitization of visceral nociceptors.
The action of estrogens at the level of primary sensory
neurons is complex and determined by the characteristics of
the target genes and coregulators, as well as, the regional
availability of E2. Several authors have suggested that the
sex diﬀerences in pain sensitivity and the prevalence of
chronic pain disorders may result from a malfunctioning
endogenous pain inhibitory response rather than an increase
nociceptive activity [41]. Many previous studies have estab-
lished connections between estrogens and the modulation of
diﬀerent nociceptive pathways. One of the mechanisms may
be estrogen inhibition of nociceptive signaling (mediated by
both P2X3 and TRPV1) through interaction with mGluR2/3.
Painful stimuli initiate action potentials in the peripheral
terminals of DRG neurons evoking release of excitatory neu-
rotransmitters such as glutamate (Figure 2). Ligand-gated
P2X receptors which can be activated by endogenous ATP
during induction of action potentials are highly expressed in
identiﬁed nociceptors [42]. Thus, E2-modulated encoding of
nociceptive stimuli at the level of primary sensory neurons
maycontributetoourunderstandingofcomplexmechanism
of nongenomic eﬀect of gonadal steroids.4 Pain Research and Treatment
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Figure 2: Proposed mechanism of estradiol eﬀect on ATP-induced [Ca2+]i signaling in primary sensory neurons. ATP released by tissue
damage acts on P2X3 receptor resulting in activation of the L-type voltage-gated calcium channel (VGCC). ERα activates mGluR2/3 which
in turn activates Gi/o signaling resulting in inhibition of adenylate-cyclase (AC). Decreased cAMP concentration reduced PKA activation
and decreased the conductance of the L-type VGCC.
4. Conclusions
The fact that homeostatic changes are similar in all “func-
tional” disorders suggests a model in which alteration in
the neuronal circuits in predisposed individuals is triggered
by the similar pathophysiology. Both physiologic and psy-
chological variables appear to play important roles in the
development of functional syndromes, and psychologically
oriented treatments have a role in their management. Pa-
tients have an altered perception of visceral sensation that is
typically manifested as hyperalgesia, an enhanced perception
of pain. Pain is the symptom that patients with functional
disorders list as the most depressing and is a major factor
for consulting a physician. The functional characteristics of
primary sensory (small diameter, presumably nociceptors)
neuronsandtheirreceptorsareusuallyinvestigatedbymeans
of a wide diversity of experimental models, both in vivo
and in vitro.S e v e r a lin vivo animal models have been
developed and characterized for speciﬁc sensory modalities,
including nociception, particularly in rodents [2]. The use
of these models suggests the advantage of a physiological/
pathological condition, and it is hence a basic step in the
understanding of the fundamental mechanisms underlying
the function of sensory systems and for the development
and proof of new possible strategies for their modulation.
As far as the modulation of receptors involved in nociceptive
input transmission is concerned, it is indeed possible to re-
produce in rodents various painful states observed in hu-
mans. The deﬁciency of suitable animal models for certain
pain syndromes requires the use of strictly controlled in vitro
paradigms in order to dissect the fundamental properties
of the basic processes. One possible approach to the study
of the functional characteristics of neurotransmitter (i.e.
ATP) release and activated ion channel receptor is the direct
recording of the receptor response to its agonist and antag-
onist on isolated cells expressing the receptor, by means of
calcium imaging or patch clamp recordings techniques. His-
tological and functional studies implied that the important
receptors involved in the transmission and modulation of
nociceptive inputs are expressed at the level of the peripheral
and/or central terminals of DRG neurons (e.g., P2X3 and
TRPV1).
Although it is generally accepted that each primary af-
ferentneuron is a single sensorychannel, severalstudies have
challenged that view and demonstrate that a population of
DRG neuron can innervate both the viscera and somatic
tissues. The design of the proposed studies using retrograde
labeling from the uterus and colon will address the pos-
sibility that the same primary aﬀerent can innervate both
reproductive and gastrointestinal organs (DRG neuron will
have both retrograde tract tracing dyes). This new subset
of dichotomizing ﬁbers provides a novel pathway for sen-
sitization of one viscus by another. Adult DRG neurons in
short-term culture retain the expression of receptors (P2X
and TRPV1) [2] which mediate the response to putative
nociceptive signals. They continue to respond to ER agonists
mimicking in vivo activation. An important advantage is that
these neurons can be studied apart from endogenous signals.
AlargebodyofliteraturesupportstheideathatE2 modulates
nociceptive responses in functional pain syndromes. Within
the context of our hypothesis, E2 modulation of nociceptive
responses depends on the type of pain, its durations, and
the involvement of other antinociceptive mechanisms. E2
modulates DRG neurons response to ATP, suggesting that
visceral aﬀerent nociceptors are modulated by E2, which may
explain the observed clinical and animal gender diﬀerences
in visceral hypersensitivity and suggests a potential target for
mediating nociception. Future direction of research should
include more experiments to study the role of peripheral
ERs in visceral nociception using in vivo models. Thus, fromPain Research and Treatment 5
a public health perspective, the outcome of this study will
have a substantial impact, because it will increase our knowl-
edge of nociceptive functional diseases, such as IBS, inter-
stitial cystitis, and chronic pelvic pain, and help achieve
a deeper understanding of gender diﬀerences presented in
clinical aspects of these symptoms associated with various
psychiatric disorders. Only a thorough understanding of
the mechanism implicated in these phenomena can truly
contribute to the design of new and more eﬃcient therapies.
Many illnesses aﬀect women and men diﬀerently. Some dis-
ordersaremorecommoninwomen,andsomeexpressthem-
selves with diﬀerent symptoms. It is very well documented
that diﬀerences between the sexes exist in the prevalence and
severity of a broad range of diseases, disorders, and condi-
tions.Incallingforgreaterfocusongender-basedbiomedical
research,theclinicalandscientiﬁccommunitieswillbebetter
equipped to identify barriers to the achievement of knowl-
edge about gender diﬀerences-including ethical, ﬁnancial,
sociological, and scientiﬁc factors. In developing countries,
painaccountsfornearly20%ofallprimaryhealthcarevisits.
Studies have shown that at least one-third of patients with
pain also suﬀer from depression and it aﬀects more women
than men. The new approach in pain research and treatment
should address a crucial question in women’s health and
in visceral nociception in particular. Reaching further, this
research is a liaison between the basic science work and the
clinical aspects that are addressed through other disciplines
such as anesthesiology (pain management), gastroenterol-
ogy, obstetrics, and gynecology.
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